The study's findings that in tumor tissues from sHA-F treated animals, there was inhibition of AKT activation, EMT effectors and angiogenesis but an induction of E-cadherin and caspase-3, confirm that the antitumor activity of sHA-F in vivo is due to the inhibition of HAase activity. The gene discussed is AKT1; the disease is neoplasm.